{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:04:21Z","timestamp":1790618661277,"version":"4.1.0"},"reference-count":109,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused extreme concern for patients with inborn errors of immunity (IEIs). In the first 6 \u200amonths of the pandemic, the case fatality rate among patients with IEIs resembled that of the general population (9%). This review aims at summarizing what we have learned about the course and outcome of coronavirus disease 2019 (COVID-19) in patients with different IEIs and what this can potentially teach us about the immune mechanisms that could confer protection or predisposition to severe disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A total of 649 patients with IEI and COVID-19 have been reported in the last year and a half, spanning all groups of the International Union of Immunological Societies classification of IEIs. For most patients, the underlying IEI does not represent an independent risk factor for severe COVID-19. In fact, some IEI may even be protective against the severe disease due to impaired inflammation resulting in less immune-mediated collateral tissue damage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>We review the characteristics of SARS-CoV-2 infection in a large number of patients with IEI. Overall, we found that combined immunodeficiencies, immune dysregulation disorders, and innate immune defects impairing type I interferon responses are associated with severe disease course.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001062","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T01:04:47Z","timestamp":1632531887000},"page":"648-656","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned"],"prefix":"10.1097","volume":"33","author":[{"given":"Giorgia","family":"Bucciol","sequence":"first","affiliation":[{"name":"Laboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven"},{"name":"Childhood Immunology, Department of Pediatrics, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart G.","family":"Tangye","sequence":"additional","affiliation":[{"name":"Garvan Institute of Medical Research, Darlinghurst"},{"name":"St Vincent's Clinical School, UNSW Sydney, Randwick, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meyts","sequence":"additional","affiliation":[{"name":"Laboratory of Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven"},{"name":"Childhood Immunology, Department of Pediatrics, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"R2-20250730","first-page":"14","article-title":"Life-threatening COVID-19: defective interferons unleash excessive inflammation","volume":"1","author":"Zhang","year":"2020","journal-title":"Med (New York, NY)"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaci.2020.07.033","article-title":"Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1","volume":"146","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaci.2021.06.024","article-title":"Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)","volume":"148","author":"Chou","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are common in the elderly and account for about 20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in \u223c1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci Immunol"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.jaip.2021.04.017","article-title":"Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity","volume":"9","author":"Milito","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R10-20250730","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-01066-8","article-title":"Outcome of SARS-CoV-2 infection in 121 patients with inborn errors of immunity: a cross-sectional study","author":"Goudouris","year":"2021","journal-title":"J Clin Immunol"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jaci.2020.04.013","article-title":"A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia","volume":"146","author":"Quinti","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s10875-021-01077-5","article-title":"COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico","volume":"41","author":"Castano-Jaramillo","year":"2021","journal-title":"J Clin Immunol"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10875-020-00928-x","article-title":"Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency","volume":"41","author":"Delavari","year":"2021","journal-title":"J Clin Immunol"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"614086","DOI":"10.3389\/fimmu.2020.614086","article-title":"Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel","volume":"11","author":"Marcus","year":"2021","journal-title":"Front Immunol"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R16-20250730","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-01065-9","article-title":"COVID-19 in patients with primary immunodeficiency","author":"Esenboga","year":"2021","journal-title":"J Clin Immunol"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"100084","DOI":"10.1016\/j.jtauto.2021.100084","article-title":"Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department","volume":"4","author":"Guchelaar","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jaip.2020.11.042","article-title":"COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency","volume":"9","author":"Grumach","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jaip.2020.11.006","article-title":"COVID-19 infection in 10 common variable immunodeficiency patients in New York City","volume":"9","author":"Cohen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00296-021-04812-8","article-title":"COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study","volume":"41","author":"G\u00fcven","year":"2021","journal-title":"Rheumatol Int"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"e150867","DOI":"10.1172\/JCI150867","article-title":"Mild COVID-19 despite autoantibodies to type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)","volume":"131","author":"Meisel","year":"2021","journal-title":"J Clin Invest"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jama.2020.13719","article-title":"Presence of genetic variants among young men with severe COVID-19","volume":"324","author":"van der Made","year":"2020","journal-title":"JAMA"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ccr3.3643","article-title":"COVID-19 in a child with primary antibody deficiency","volume":"9","author":"Ahanchian","year":"2021","journal-title":"Clin Case Rep"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jaci.2020.09.020","article-title":"Severe SARS-CoV-2 disease in the context of a NF-\u03baB2 loss-of-function pathogenic variant","volume":"147","author":"Abraham","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.anai.2020.06.006","article-title":"Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin","volume":"125","author":"Aljaberi","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12026-021-09184-6","article-title":"Management of COVID-19 pneumonia in a child with NEMO deficiency","volume":"69","author":"Alkan","year":"2021","journal-title":"Immunol Res"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"e929447","DOI":"10.12659\/AJCR.929447","article-title":"The clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia","volume":"22","author":"Almontasheri","year":"2021","journal-title":"Am J Case Rep"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40618-020-01323-4","article-title":"A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy Italy: letter to the","volume":"43","author":"Beccuti","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1038\/s41467-020-19761-2","article-title":"Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report","volume":"11","author":"Buckland","year":"2020","journal-title":"Nat Commun"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/pai.13322","article-title":"A male infant with COVID-19 in the context of ARPC1B deficiency","volume":"32","author":"Castano-Jaramillo","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"R32-20250730","article-title":"Severe COVID-19 pneumonia in Good syndrome with a favorable outcome","author":"Cos Esquius","year":"2021","journal-title":"Clin Immunol"},{"key":"R33-20250730","first-page":"00035-5","article-title":"Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency \u2013 Three consecutive cases and review of the literature","volume":"S0213-005X","author":"Delgado-Fern\u00e1ndez","year":"2021","journal-title":"Enfermedades Infecc Microbiol Cl\u00edn"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.anai.2020.04.033","article-title":"The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease","volume":"125","author":"Fill","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1007\/s10875-021-01081-9","article-title":"SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?","volume":"41","author":"Guisado Hern\u00e1ndez","year":"2021","journal-title":"J Clin Immunol"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000514193","article-title":"SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency","volume":"182","author":"Gupta","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaip.2020.09.052","article-title":"Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City","volume":"9","author":"Ho","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaip.2020.08.053","article-title":"IFN-\u03b3 receptor 2 deficiency initial mimicry of multisystem inflammatory syndrome in children (MIS-C)","volume":"9","author":"Jin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"645989","DOI":"10.3389\/fimmu.2021.645989","article-title":"Case report: convalescent plasma achieves SARS-CoV-2 viral clearance in a patient with persistently high viral replication over 8 weeks due to severe combined immunodeficiency (SCID) and graft failure","volume":"12","author":"Keitel","year":"2021","journal-title":"Front Immunol"},{"key":"R40-20250730","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17669","article-title":"Primary haemophagocytic lymphohistiocytosis (Ch\u00e9diak\u2013Higashi syndrome) triggered by acute SARS-CoV-2 infection in a 6-week-old infant","author":"Lange","year":"2021","journal-title":"Br J Haematol"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2021.03.034","article-title":"Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis","volume":"148","author":"Lemarquis","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10875-020-00904-5","article-title":"Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy","volume":"41","author":"London","year":"2021","journal-title":"J Clin Immunol"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10875-020-00896-2","article-title":"Recovery from COVID-19 in a child with chronic granulomatous disease and T cell lymphopenia","volume":"41","author":"Mantravadi","year":"2021","journal-title":"J Clin Immunol"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.jaip.2020.06.046","article-title":"Rapid recovery of a SARS-CoV-2\u2013infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma","volume":"8","author":"Mira","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.anai.2020.08.017","article-title":"A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency","volume":"126","author":"Mullur","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"108644","DOI":"10.1016\/j.clim.2020.108644","article-title":"Fatal SARS-CoV-2 infection in a male patient with Good's syndrome","volume":"223","author":"Pozzi","year":"2021","journal-title":"Clin Immunol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41525-021-00220-w","article-title":"TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19","volume":"6","author":"Schmidt","year":"2021","journal-title":"Npj Genomic Med"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"596761","DOI":"10.3389\/fimmu.2020.596761","article-title":"Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19","volume":"11","author":"Van Damme","year":"2020","journal-title":"Front Immunol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"108662","DOI":"10.1016\/j.clim.2020.108662","article-title":"SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency","volume":"224","author":"van Oers","year":"2021","journal-title":"Clin Immunol"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12016-016-8591-2","article-title":"An update on the use of immunomodulators in primary immunodeficiencies","volume":"52","author":"Vignesh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41409-020-01041-8","article-title":"COVID-19 after hematopoietic stem cell transplantation: report of two children","volume":"56","author":"Zamperlini-Netto","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12879-020-05231-z","article-title":"Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.anai.2020.08.360","article-title":"COVID-19 in a patient with CVID and contraindications to several potential treatments","volume":"125","author":"Ender","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R54-20250730","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-01093-5","article-title":"Self-limited COVID-19 in a patient with artemis hypomorphic SCID","author":"Gabryszewski","year":"2021","journal-title":"J Clin Immunol"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.anai.2020.08.354","article-title":"Complications of coronavirus in a patient with CVID","volume":"125","author":"Urschel","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"(Suppl 1)","key":"R56-20250730","first-page":"S1","article-title":"COVID-19 in 3 patients with CLTA4 haploinsufficiency and absence of autoantibodies to type 1 interferons","volume":"41","author":"Ochoa","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl 1)","key":"R57-20250730","first-page":"S1","article-title":"The clinical coarse and outcome of SARS-COVID 19 in patients with inborn error of immunity, does it relate to the type of the immune defects","volume":"41","author":"Sherkat","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl 1)","key":"R58-20250730","first-page":"S1","article-title":"Treatment of COVID-19 with convalescent plasma in a patient with X-linked agammaglobulinemia","volume":"41","author":"Dhamija","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl 1)","key":"R59-20250730","first-page":"S1","article-title":"High dose intravenous immunoglobulin. The next step in therapy for severe COVID19 infection?","volume":"41","author":"Mejia","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl 1)","key":"R60-20250730","first-page":"S1","article-title":"Positive SARS-CoV-2 RT-PCR testing in a pediatric patient with X-linked agammaglobulinemia","volume":"41","author":"Westreich","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl 1)","key":"R61-20250730","first-page":"S1","article-title":"A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma","volume":"41","author":"Iaboni","year":"2021","journal-title":"J Clin Immunol"},{"issue":"(Suppl. 1)","key":"R62-20250730","first-page":"S1","article-title":"Confirmed SARS-COV-2 infection in a cohort of children and young adults with moderate or severe primary immunodeficiencies","volume":"41","author":"Dey\u00e0-Martinez","year":"2021","journal-title":"J Clin Immunol"},{"key":"R63-20250730","first-page":"S1","article-title":"Clinical outcomes of SARS-CoV2 infection in STAT3 deficiency","volume":"41","author":"Khalid","year":"2021","journal-title":"J Clin Immunol"},{"key":"R64-20250730","article-title":"Surprising protective mechanisms against severe forms of COVID-19 infection among common variable immunodeficiency patients-one center experience","author":"Petricau","year":"2020","journal-title":"Res Sq"},{"key":"R65-20250730","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"R66-20250730","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"G\u00f6tzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"R67-20250730","doi-asserted-by":"crossref","first-page":"1146-1153","DOI":"10.1007\/s10875-021-01046-y","article-title":"Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency","volume":"41","author":"Kinoshita","year":"2021","journal-title":"J Clin Immunol"},{"key":"R68-20250730","doi-asserted-by":"crossref","first-page":"e240765","DOI":"10.1136\/bcr-2020-240765","article-title":"Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia","volume":"14","author":"Loh","year":"2021","journal-title":"BMJ Case Rep CP"},{"key":"R69-20250730","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3855\/jidc.13840","article-title":"Atypical course of COVID-19 in patient with Bruton agammaglobulinemia","volume":"14","author":"Milo\u0161evi\u0107","year":"2020","journal-title":"J Infect Dev Ctries"},{"key":"R70-20250730","doi-asserted-by":"crossref","first-page":"e28382","DOI":"10.1002\/pbc.28382","article-title":"COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation","volume":"67","author":"Wahlster","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R71-20250730","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.147.3MA5.453","article-title":"Varying illness severity in patients with MyD88 deficiency infected with coronavirus SARS-CoV-2","volume":"147","author":"Mahmood","year":"2021","journal-title":"Pediatrics"},{"key":"R72-20250730","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R73-20250730","first-page":"69","article-title":"Severe outcomes among patients with coronavirus disease 2019 (COVID-19) \u2013 United States","volume":"2020","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R76-20250730","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","article-title":"Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma","volume":"41","author":"Vazquez","year":"2021","journal-title":"J Clin Immunol"},{"key":"R77-20250730","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","article-title":"Autoantibodies against type I interferons are associated with multiorgan failure in COVID-19 patients","volume":"47","author":"Koning","year":"2021","journal-title":"Intensive Care Med"},{"key":"R78-20250730","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain","volume":"41","author":"Troya","year":"2021","journal-title":"J Clin Immunol"},{"key":"R79-20250730","article-title":"Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19","author":"Wijst","year":"2021","journal-title":"bioRxiv"},{"key":"R80-20250730","article-title":"Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"medRxiv"},{"key":"R81-20250730","doi-asserted-by":"crossref","first-page":"e20211211","DOI":"10.1084\/jem.20211211","article-title":"Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs","volume":"218","author":"Lopez","year":"2021","journal-title":"J Exp Med"},{"key":"R82-20250730","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1371\/journal.pmed.0030289","article-title":"Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1","volume":"3","author":"Meager","year":"2006","journal-title":"PLoS Med"},{"key":"R83-20250730","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/MD.0b013e3181fd8ec3","article-title":"Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency","volume":"89","author":"Picard","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"R84-20250730","doi-asserted-by":"crossref","first-page":"e1000240","DOI":"10.1371\/journal.ppat.1000240","article-title":"MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV","volume":"4","author":"Sheahan","year":"2008","journal-title":"PLOS Pathog"},{"key":"R85-20250730","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","article-title":"An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study","volume":"395","author":"Verdoni","year":"2020","journal-title":"Lancet"},{"key":"R86-20250730","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cell.2020.09.034","article-title":"Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)","volume":"183","author":"Gruber","year":"2020","journal-title":"Cell"},{"key":"R87-20250730","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s10875-020-00941-0","article-title":"Distinctive features of Kawasaki disease following SARS-CoV-2 infection: a controlled study in Paris, France","volume":"41","author":"Toubiana","year":"2021","journal-title":"J Clin Immunol"},{"key":"R88-20250730","doi-asserted-by":"crossref","first-page":"e20210446","DOI":"10.1084\/jem.20210446","article-title":"SARS-CoV-2\u2013related MIS-C: a key to the viral and genetic causes of Kawasaki disease?","volume":"218","author":"Sancho-Shimizu","year":"2021","journal-title":"J Exp Med"},{"key":"R89-20250730","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15585\/mmwr.mm6940e1","article-title":"Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection \u2013 United Kingdom and United States March\u2013August","volume":"69","author":"Morris","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R90-20250730","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. children and adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"N Engl J Med"},{"key":"R91-20250730","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fonc.2014.00307","article-title":"Good syndrome, bad problem","volume":"4","author":"Martinez","year":"2014","journal-title":"Front Oncol"},{"key":"R92-20250730","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64012-3","article-title":"Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease","volume":"350","author":"Meager","year":"1997","journal-title":"Lancet"},{"key":"R93-20250730","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2249.2003.02113.x","article-title":"Anticytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and\/or myasthenia gravis","volume":"132","author":"Meager","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"R94-20250730","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1182\/blood-2010-05-286161","article-title":"Anticytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia","volume":"116","author":"Burbelo","year":"2010","journal-title":"Blood"},{"key":"R95-20250730","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"R96-20250730","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fped.2016.00107","article-title":"Unbalanced immune system: immunodeficiencies and autoimmunity","volume":"4","author":"Giardino","year":"2016","journal-title":"Front Pediatr"},{"key":"R97-20250730","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1093\/cid\/civ269","article-title":"Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications","volume":"61","author":"Malphettes","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R98-20250730","doi-asserted-by":"crossref","first-page":"eabd0110","DOI":"10.1126\/sciimmunol.abd0110","article-title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19","volume":"5","author":"Roschewski","year":"2020","journal-title":"Sci Immunol"},{"key":"R99-20250730","doi-asserted-by":"crossref","first-page":"108027","DOI":"10.1016\/j.intimp.2021.108027","article-title":"Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"99","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R100-20250730","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10875-021-01068-6","article-title":"Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-\u03b2","volume":"41","author":"Vinh","year":"2021","journal-title":"J Clin Immunol"},{"key":"R101-20250730","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10875-021-01023-5","article-title":"Interferon-\u03b2 therapy in a patient with incontinentia pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2","volume":"41","author":"Bastard","year":"2021","journal-title":"J Clin Immunol"},{"key":"R102-20250730","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10875-020-00933-0","article-title":"IFN-\u03b12a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2","volume":"41","author":"L\u00e9vy","year":"2021","journal-title":"J Clin Immunol"},{"key":"R103-20250730","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13054-020-03171-3","article-title":"Plasma exchange in critically ill COVID-19 patients","volume":"24","author":"Morath","year":"2020","journal-title":"Crit Care"},{"key":"R104-20250730","doi-asserted-by":"crossref","first-page":"108408","DOI":"10.1016\/j.clim.2020.108408","article-title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19","volume":"214","author":"Ma","year":"2020","journal-title":"Clin Immunol"},{"key":"R105-20250730","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10875-021-00994-9","article-title":"Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia","volume":"41","author":"de Prost","year":"2021","journal-title":"J Clin Immunol"},{"key":"R106-20250730","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"R107-20250730","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N Engl J Med"},{"key":"R108-20250730","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/v13071202","article-title":"Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail","volume":"13","author":"Drouin","year":"2021","journal-title":"Viruses"},{"key":"R109-20250730","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R110-20250730","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.anai.2021.05.015","article-title":"Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency","volume":"127","author":"Squire","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R111-20250730","article-title":"Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies","author":"Fox","year":"2021","journal-title":"medRxiv"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:10:49Z","timestamp":1753899049000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001062","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}